LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients’ survival an extra 4.8 months, it might also result in some adverse effects via inducing the neuroendocrine differentiation (NED). Here we found that lncRNA-p21 is highly expressed in the NEPC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Luo, Jie, Wang, Keliang, Yeh, Shuyuan, Sun, Yin, Liang, Liang, Xiao, Yao, Xu, Wanhai, Niu, Yuanjie, Cheng, Liang, Maity, Sankar N., Jiang, Runze, Chang, Chawnshang
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561926/
https://ncbi.nlm.nih.gov/pubmed/31189930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09784-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados